Taylor JJ, Newberger NG, Stern AP, et al. - Researchers conducted the study for calculating repetitive transcranial magnetic stimulation (rTMS) seizure rates across various FDA-cleared devices in naturalistic clinical settings. In July and August 2018, about 500 members of the Clinical TMS Society were electronically surveyed about seizures in their practices. The survey was completed by 134 members, with 9 responses being excluded due to inconsistencies in the data. A total of 18 seizures were reported in 586,656 sessions and 25,526 patients across all device manufacturers. Data reported that the overall seizure rate was 0.31 per 10,000 sessions and 0.71 per 1,000 patients. Although the absolute risk of a seizure is low with rTMS, generic Brainsway H-coil treatment seems to be associated with a higher relative risk than generic figure-8 coil treatment.